tbuckley/cabot-search huggingface dataset:
Persistency of chlamydia pneumoniae in degenerative aortic valve stenoses indicated by heat shock protein 60 homologues Dirk Skowasch, Silvia Lentini, Ren� Andri�, James A. Likungu, Armin Welz, Berndt L�deritz, Gerhard Bauriedel. Heart Center University Bonn, Bonn, Germany
Journal: Journal of the American College of Cardiology (2001)
Error in Author Name and Affilations
Journal: JAMA Network Open (2021)

Stine Munk Hald, MD; Sören Möller, PhD; Luis Alberto García Rodríguez, MD; Rustam Al-Shahi Salman, PhD; Mike Sharma, MSc; Hanne Christensen, DMSc; Maja Hellfritzsch, MD, PhD; Anton Pottegård, DMSc; Jesper Hallas, DMSc; David Gaist, MD, PhD
Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis
Authors: Cheng Han Ng, Jieling Xiao, Wen Hui Lim, Yip Han Chin, Jie Ning Yong, Darren Jun Hao Tan, Phoebe Tay, Nicholas Syn, Roger Foo, Mark Chan, Nicholas Chew, Eunice XX Tan, Daniel Q. Huang, Yock Young Dan, Nobuharu Tamaki, Mohammad Shadab Siddiqui, Arun J. Sanyal, Rohit Loomba, Mazen Noureddin, Mark D. Muthiah
Journal: Hepatology (2022)

Abstract Background and Aims The evaluation of the natural history of NASH has been limited. Currently, liver biopsy remains the gold standard in the assessment of NASH. Placebo‐controlled trials represent a controlled environment with paired biopsies for the evaluation of NASH. This meta‐analysis thus seeks to quantify the change severity of NASH over time, with patients on placebo arms from randomized controlled trials (RCTs) to examine the natural history of NASH. Methods A search was conducted to include NASH RCTs with placebo treatment arms. Primary outcomes were (1) the resolution of NASH without worsening of fibrosis, (2) two‐point reduction in NAFLD activity score without worsening of fibrosis, and (3) at least one‐point reduction in fibrosis. Generalized linear mix model was used to estimate pooled proportion and mean differences. Results This meta‐analysis of 43 RCTs included 2649 placebo‐treated patients. The pooled estimate of NASH resolution and two‐point NAFLD activity score reduction without worsening of fibrosis was 11.65% (95% CI: 7.98‐16.71) and 21.11% (95% CI: 17.24‐25.57). The rate of ≥1 stage reduction and progression of fibrosis was 18.82% (95% CI: 15.65‐22.47) and 22.74% (CI: 19.63‐26.17), respectively. Older age and African American ethnicity was associated with lower NASH resolution rate in placebo‐treated patients. Conclusions Despite the absence of any pharmacological interventions, a significant proportion of patients in the placebo arm demonstrated improvements in liver histology, highlighting the possibility that NASH is a disease that can not only progress but regress spontaneously over time. Additionally, histologic response in placebo‐treated patients is helpful in future design of phase 2B and phase 3 trials.
Correction of left ventricular dyssynchrony by left ventricular-based pacing in patients with severe heart failure and left bundle branch block Yves Etienne, Philippe Guillo, Jacques Mansourati, Abdelkader Touiza, Martine Gilard, Yves Bizais, Jean-Jacques Blanc. University Hospital of Brest, Brest, France
Journal: Journal of the American College of Cardiology (2001)
Journal of Cardiovascular Risk
Authors: Beverly Renford
Journal: JAMA (1995)

The<i>Journal of Cardiovascular Risk</i>seeks to establish its own niche through both an emphasis on the management of cardiovascular risk factors and a review of current research. Although these topics appear in other journals in the cardiovascular field,<i>Journal of Cardiovascular Risk</i>provides a forum in which risk factors are the major focus. From this perspective, the "Review in Depth" section is a significant strength. Although these reviews are commissioned works, they are similar to the formal conferences and continuing education sessions that several of the professional societies in the cardiovascular field conduct on a regular basis. The topics covered are timely. Examples include lipoproteins and coronary heart disease, target organ damage in hypertension, and ambulatory blood pressure monitoring. Each issue begins with an overview of the topic by the senior author followed by a series of focused articles on subtopics that emphasize the clinical implications and management strategies.
Silent ischemia during daily life is related to increased thrombin generation in patients with chronic stable angina Ignatios Ikonomidis, Felicitta Andreotti, Christodoulos Stefanadis, Christos Pitsavos, Emanuel Economou, Pavlos Toutouzas, Petros Nihoyannopoulos. Hammersmith Hospital, London, Greece, Ippokration Hospital, Athens, Greece
Journal: Journal of the American College of Cardiology (2001)
International Conference on Prostaglandins and Cancer 1981
Journal: JNCI Journal of the National Cancer Institute (1981)

International Conference on Prostaglandins and Cancer 1981 JNCI: Journal of the National Cancer Institute, Volume 66, Issue 3, March 1981, Page 609, https://doi.org/10.1093/jnci/66.3.609-b Published: 01 March 1981
Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Authors: Jennifer L. Taylor-Cousar, Anne Munck, Edward F. McKone, Cornelis K. van der Ent, Alexander Moeller, Christopher Simard, Linda T. Wang, Edward P. Ingenito, Charlotte McKee, Yimeng Lu, Julie Lekstrom-Himes, J. Stuart Elborn
Journal: New England Journal of Medicine (2017)

Combination treatment with the cystic fibrosis transmembrane conductance regulator (CFTR) modulators tezacaftor (VX-661) and ivacaftor (VX-770) was designed to target the underlying cause of disease in patients with cystic fibrosis.
Hypofractionated Radiotherapy for Locally Advanced Non–Small Cell Lung Cancer—Does Size Matter?
Authors: Nitin Ohri, Maria Werner-Wasik
Journal: JAMA Oncology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Queries and Minor Notes
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluating the Patient With a Pulmonary Nodule
Authors: Peter J. Mazzone, Louis Lam
Journal: JAMA (2022)

<h3>Importance</h3> Pulmonary nodules are identified in approximately 1.6 million patients per year in the US and are detected on approximately 30% of computed tomographic (CT) images of the chest. Optimal treatment of an individual with a pulmonary nodule can lead to early detection of cancer while minimizing testing for a benign nodule. <h3>Observations</h3> At least 95% of all pulmonary nodules identified are benign, most often granulomas or intrapulmonary lymph nodes. Smaller nodules are more likely to be benign. Pulmonary nodules are categorized as small solid (&lt;8 mm), larger solid (≥8 mm), and subsolid. Subsolid nodules are divided into ground-glass nodules (no solid component) and part-solid (both ground-glass and solid components). The probability of malignancy is less than 1% for all nodules smaller than 6 mm and 1% to 2% for nodules 6 mm to 8 mm. Nodules that are 6 mm to 8 mm can be followed with a repeat chest CT in 6 to 12 months, depending on the presence of patient risk factors and imaging characteristics associated with lung malignancy, clinical judgment about the probability of malignancy, and patient preferences. The treatment of an individual with a solid pulmonary nodule 8 mm or larger is based on the estimated probability of malignancy; the presence of patient comorbidities, such as chronic obstructive pulmonary disease and coronary artery disease; and patient preferences. Management options include surveillance imaging, defined as monitoring for nodule growth with chest CT imaging, positron emission tomography–CT imaging, nonsurgical biopsy with bronchoscopy or transthoracic needle biopsy, and surgical resection. Part-solid pulmonary nodules are managed according to the size of the solid component. Larger solid components are associated with a higher risk of malignancy. Ground-glass pulmonary nodules have a probability of malignancy of 10% to 50% when they persist beyond 3 months and are larger than 10 mm in diameter. A malignant nodule that is entirely ground glass in appearance is typically slow growing. Current bronchoscopy and transthoracic needle biopsy methods yield a sensitivity of 70% to 90% for a diagnosis of lung cancer. <h3>Conclusions and Relevance</h3> Pulmonary nodules are identified in approximately 1.6 million people per year in the US and approximately 30% of chest CT images. The treatment of an individual with a pulmonary nodule should be guided by the probability that the nodule is malignant, safety of testing, the likelihood that additional testing will be informative, and patient preferences.
Off-pump versus on-pump CABG surgery: Determinants and surgical outcomes among 51 surgeons doing both procedures Michael J. Mack, April W. Simon, Edmund R. Becker, Steven D. Culler, Lynn G. Tarkington, Salvatore Battaglia, Michael P. Macris, Sameer Mehta. Medical City Dallas, Dallas, TX, Emory University Rollins School of Public Health, Atlanta, GA
Journal: Journal of the American College of Cardiology (2001)
Linear lesion continuity in MAZE-oriented catheter ablation of atrial fibrillation: Evaluation during ablation and after 6 months with a new noncontact-mapping system Ali Erdogan, Joerg Carlsson, Alexander Berkowitsch, Britta Schulte, Joerg Neuzner, Heinz F. Pitschner. Kerchoff Heart Center, Dept. of Cardiology, Bad Nauheim, Germany
Journal: Journal of the American College of Cardiology (2001)
Abstract 248: Elamipretide Reverses Dysregulation of mRNA Expression Levels of FoxO Transcription Factors 1, 3a and 4 in Left Ventricular Myocardium of Dogs with Advanced Heart Failure
Authors: Ramesh C Gupta, Vinita Singh-Gupta, Kefei Zhang, Jiang Xu, Hani N Sabbah
Journal: Circulation Research (2017)

Background: FoxO (Forkhead box) family of transcription factors play important roles in regulating the expression of genes involved in physiologic cellular functions that include 1) cell proliferation and growth, 2) oxidative stress and DNA repair, 3) apoptosis and autophagy, 4) energy metabolism and 5) immune system function. Many components of all 5 cellular functions are abnormal in the failing heart. FoxO1, FoxO3, and FoxO4 are members of the FoxO family and are expressed in adult cardiomyocytes. We previously showed that elamipretide (ELAM), a novel mitochondria-targeting peptide, reverses many of the abnormalities of the above captioned cellular function in dogs with advanced heart failure (HF). Abnormalities of expression and/or phosphorylation of FoxO1, FoxO3a and FoxO4 have been described in HF. Objective: This study examined the effects of chronic therapy with ELAM on levels of mRNA expression of FoxO1, FoxO3a and FoxO4 in LV myocardium of dogs with coronary microembolization-induced HF (LV ejection fraction ~30%). Methods: LV tissue from 14 HF dogs randomized to 3 months monotherapy with subcutaneous injections of ELAM (0.5 mg/kg once daily, n=7) or no therapy at all (control, CON, n=7) and tissue from 6 normal (NL) dogs was used in the study. Using specific primers, mRNA levels of FoxO1, FoxO3a, and FoxO4 normalized to β-actin, an internal control, were measured using real-time PCR in isolated RNA from LV tissue. Results: There were no differences in the levels of β-actin among the 3 study groups. mRNA expression levels of FoxO1 and 3a were significantly decreased and FoxO4 increased in HF-CON dogs compared to NL dogs (0.16, 0.19, and 2.48 fold change from NL respectively, p&lt;0.05). Treatment of HF dogs with ELAM restored the expression of all 3 FoxO transcription factors to near NL (0.53, 0.65, and 1.21 fold change from NL respectively, P&lt;0.05 vs. CON). Conclusions: mRNA levels of FoxO1 and FoxO3a are reduced and that of FoxO4 is increased in LV myocardium of HF dogs. Chronic therapy with ELAM normalizes expression of all 3 FoxO transcription factors. This improvement in FoxO expression is consistent with the observed reduction of oxidative stress, apoptosis and cytokines and improved energy metabolism in HF dogs following chronic therapy with ELAM.
Sucralfate
Authors: John A. Oates, Alastair J.J. Wood, Denis M. McCarthy
Journal: New England Journal of Medicine (1991)

John A. Oates, M.D., Editor Alastair JJ. Wood, M.D., Associate Editor jTHE past 10 years have witnessed major changes in our understanding of the pathogenesis and treatment of what are commonly called the acid-peptic diseases. Schwarz's dictum — "without acid gastric juice, no peptic ulcer" — still applies.1 Increasingly, however, ulcers have come to be seen as areas of mucosa in which the effects of all noxious influences have exceeded the restorative capacities of all processes favorable to mucosal repair and integrity. A major stimulus to the growth of our knowledge in this area has been the development of . . .
A Correction.
Authors: Theodore Potter
Journal: JAMA (1891)

<h3>To the Editor:</h3> —In the issue ofThe Journalcontaining the report of the Mississippi Valley Medical Association meeting at Louisville, referring to my paper upon "Certainty in the Diagnosis of Tuberculosis" I am quoted as saying: "The disease is void of the slightest tendency to self-limitation." This I certainly did not say, nor did Dr. Porter, of St. Louis, in his interesting paper published in the same number ofThe Journal, take any such extreme grounds. He called in question Flint's doctrine of self-limitation, restricting the skepticism to cases which had advanced so far that the presence of disease could be established by physical signs. It was upon a series of such cases that Flint's teaching was based. Owing to pressure of time neither Dr. Porter's paper nor mine was discussed, but in conversation with him afterward he clearly explained his position, and I think I am correct in
Treatment IND for AIDS-Related Wasting Authorized
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes
Authors: Bruce A. Perkins, Ionut Bebu, Xiaoyu Gao, Amy B. Karger, Irl B. Hirsch, Harsha Karanchi, Mark E. Molitch, Bernard Zinman, John M. Lachin, Ian H. de Boer
Journal: Diabetes Care (2022)

OBJECTIVE Rapid loss of estimated glomerular filtration rate (eGFR) within its normal range has been proposed as a strong predictor of future kidney disease. We investigated this association of eGFR slope early in the course of type 1 diabetes with long-term incidence of kidney and cardiovascular complications. RESEARCH DESIGN AND METHODS The annual percentage change in eGFR (slope) was calculated during the Diabetes Control and Complications Trial (DCCT) for each of 1,441 participants over a mean of 6.5 years and dichotomized by the presence or absence of early rapid eGFR loss (slope ≤−3% per year) as the exposure of interest. Outcomes were incident reduced eGFR (eGFR &amp;lt;60 mL/min/1.73 m2), composite cardiovascular events, or major adverse cardiovascular events (MACE) during the subsequent 24 years post-DCCT closeout follow-up. RESULTS At DCCT closeout (the baseline for this analysis), diabetes duration was 12 ± 4.8 years, most participants (85.9%) had normoalbuminuria, mean eGFR was 117.0 ± 13.4 mL/min/1.73 m2, and 149 (10.4%) had experienced early rapid eGFR loss over the preceding trial phase. Over the 24-year subsequent follow-up, there were 187 reduced eGFR (6.3 per 1,000 person-years) and 113 MACE (3.6 per 1,000 person-years) events. Early rapid eGFR loss was associated with risk of reduced eGFR (hazard ratio [HR] 1.81, 95% CI 1.18–2.79, P = 0.0064), but not after adjustment for baseline eGFR level (HR 0.94, 95% CI 0.53–1.66, P = 0.84). There was no association with composite cardiovascular events or MACE. CONCLUSIONS In people with type 1 diabetes primarily with normal eGFR and normoalbuminuria, the preceding slope of eGFR confers no additional association with kidney or cardiovascular outcomes beyond knowledge of an individual’s current level.
Whale Rider
Authors: U. Tayal
Journal: BMJ (2003)

Written and directed by Niki Caro On general release Rating: ![Graphic][1]</img>![Graphic][2]</img> Whale Rider is a film about indigenous people and the struggles that they can face to preserve their traditional way of life. Although this is not specifically a film about indigenous health, it starkly portrays the sort of unglamorous social and cultural conditions that are likely to take their toll on health, and commonly do in indigenous communities around the world: shack houses, unemployment, drugs, and children smoking. Set in the small town of Whangara, New Zealand, Whale Rider tells the story of a real-life … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif
What angiographic measure of extent of coronary artery disease best predicts subsequent risk? David B. Jessup, Joseph B. Muhlestein, Dale G. Renlund, Benjamin D. Horne, Tami L. Bair, Robert R. Pearson, Jeffrey L. Anderson. University of Utah, Salt Lake City, UT, LDS Hospital, Salt Lake City, UT
Journal: Journal of the American College of Cardiology (2001)
Chronic Enteric Carriers and Their Treatment.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Corrigendum to “Clustering and Internalization of Integrin αvβ3 With a Tetrameric RGD-synthetic Peptide”
Authors: Lucie Sancey, Elisabeth C Garanger, Stéphanie Deville-Foillard, Guy Schoehn, Amandine Hurbin, Corinne Albiges-Rizo, Didier Boturyn, Alexei Grichine, Pascal Dumy, Jean-Luc Coll
Journal: Molecular Therapy (2009)
Pharmacological treatments for psychotic symptoms in dementia: A systematic review with pairwise and network meta-analysis
Authors: Yu-Yuan Huang, Teng Teng, Xue-Ning Shen, Shi-Dong Chen, Rong-Ze Wang, Rui-Qi Zhang, Kai-Xi Dou, Xiao-Ling Zhong, Jun Wang, Ke-Liang Chen, Qian-Hua Zhao, Lan Tan, Qiang Dong, Xin-Yu Zhou, Jin-Tai Yu
Journal: Ageing Research Reviews (2022)
DANGER IN SIMILARITY OF ETHER AND CHLOROFORM CONTAINERS
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal